Aeglea Biotherapeutics Inc (AGLE)
US Market

Aeglea Biotherapeutics (AGLE) Stock Price & Analysis


AGLE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.66 - $39.00
Previous Close$11.3
Average Volume (3M)52.16K
Market Cap
Enterprise Value-$183.67M
Total Cash (Recent Filing)$235.36M
Total Debt (Recent Filing)$4.33M
Price to Earnings (P/E)-0.2
Nov 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-73.71
Shares Outstanding4,047,717
10 Day Avg. Volume24,042
30 Day Avg. Volume52,156
Standard Deviation0.41
Financial Highlights & Ratios
Price to Book (P/B)-0.23
Price to Sales (P/S)66.48
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-149.57
Enterprise Value/Gross Profit-78.86
Enterprise Value/Ebitda0.68
Price Target Upside120.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Aeglea Biotherapeutics Inc’s price range in the past 12 months?
Aeglea Biotherapeutics Inc lowest stock price was $2.66 and its highest was $39.00 in the past 12 months.
    What is Aeglea Biotherapeutics Inc’s market cap?
    Currently, no data Available
    When is Aeglea Biotherapeutics Inc’s upcoming earnings report date?
    Aeglea Biotherapeutics Inc’s upcoming earnings report date is Nov 09, 2023 which is in 36 days.
      How were Aeglea Biotherapeutics Inc’s earnings last quarter?
      Aeglea Biotherapeutics Inc released its earnings results on Aug 11, 2023. The company reported -$56.253 earnings per share for the quarter, missing the consensus estimate of -$3.485 by -$52.768.
        Is Aeglea Biotherapeutics Inc overvalued?
        According to Wall Street analysts Aeglea Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aeglea Biotherapeutics Inc pay dividends?
          Aeglea Biotherapeutics Inc does not currently pay dividends.
          What is Aeglea Biotherapeutics Inc’s EPS estimate?
          Aeglea Biotherapeutics Inc’s EPS estimate is -$0.85.
            How many shares outstanding does Aeglea Biotherapeutics Inc have?
            Aeglea Biotherapeutics Inc has 4,047,717 shares outstanding.
              What happened to Aeglea Biotherapeutics Inc’s price movement after its last earnings report?
              Aeglea Biotherapeutics Inc reported an EPS of -$56.253 in its last earnings report, missing expectations of -$3.485. Following the earnings report the stock price went down -4.726%.
                Which hedge fund is a major shareholder of Aeglea Biotherapeutics Inc?
                Among the largest hedge funds holding Aeglea Biotherapeutics Inc’s share is Fairmount Funds Management Llc. It holds Aeglea Biotherapeutics Inc’s shares valued at 4M.


                  Aeglea Biotherapeutics Stock Smart Score

                  The Aeglea Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aeglea Biotherapeutics Inc

                  Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.


                  Top 5 ETFs holding AGLE

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold AGLE. The ETFs are listed according to market value of AGLE within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Apellis Pharmaceuticals
                  Aslan Pharmaceuticals
                  Applied Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis